

GI Workshop References:

For Informational Purposes if Interested. These are not required to study for the Written Examination for Board Certification. Questions are taken from the material presented at the Triennial meeting and PDF slide decks posted for LFTs and hepatitis B

Liver Function Tests

1. Rigatti SJ, Stout R, "Association of Liver Function Tests with Mortality in an Insurance Applicant Population", *J Insur Med*, 2022; 49:172-182.
2. Ling S, Diao J, et al., "Associations Between Serum Levels of Liver Function Biomarkers and All-Cause and Cause-Specific Mortality: A Prospective Cohort Study", *BMC Public Health*, 2024 Nov 27; 24(1):3302. Doi: 10.1186/s12889-024-20773-6.
3. Grob SR, Suter F, et al., "The Association Between Liver Enzymes and Mortality Stratified by Non-Alcoholic Fatty Liver Disease: An Analysis of NHANES III", *Nutrients*, 2023 Jul 7; 15(13):3063. doi: 10.3390/nu15133063.
4. Albhaisi S, Qayyum R, "The Association Between Liver Enzymes and Cancer Mortality", *Clin Exp Med*, 2022 Feb;22(1):75-81.
5. Sung KC, Ryu S, et al., "Gamma-Glutamyl Transferase is Associated with Mortality Outcomes Independently of Fatty Liver", *Clin Chem*, 2015;61:1173-1181.
6. Rahmani J, Miri A, et al., "Elevated Liver Enzymes and Cardiovascular Mortality: A Systematic Review and Dose-Response Meta-Analysis of More than One Million Participants", *Eur J Gastroenterol Hepatol*, 31:555-562.
7. Yokoyama M, Watanabe T, et al., "Association of the Aspartate Aminotransferase to Alanine Aminotransferase Ratio with BNP Level and Cardiovascular Mortality in the General Population: The Yamagata Study 10-Year Follow-Up", *Dis Markers*, 2016:4857917 doi: 10.1155/2016/4857917.
8. Unalp-Arida A, Ruhl CE, "Noninvasive Fatty Liver Markers Predict Liver Disease Mortality in the U.S. Population", *Hepatology*, 2016; 63:1170-1183.
9. Kunutsor SK, Apekey TA, et al., "Liver Enzymes and Risk of All-Cause Mortality in General Populations: A Systemic Review and Meta-analysis", *Int j Epidemiol*, 2014; 43:187-201.
10. Koehler EM, Sanna D, et al., "Serum Enzymes are Associated with All-Cause Mortality in an Elderly Population", *Liver Int*, 2014; 34:296-304.
11. Fulks M, Stout RL, Dolan VF, "Using Liver Enzymes as Screening Tests to Predict Mortality Risk", *J Insur Med*, 2008; 40:191-203.
12. Lee TH, Kim WR, et al., "Serum Aminotransferase Activity and Mortality Risk in a United States Community", *Hepatology*, 2008; 47:880-887.
13. Oh CM, Won YJ, et al., "Alanine Aminotransferase and Gamma-Glutamyl Transferase Have Different Dose-Response Relationships with Risk of Mortality by Age", *Liver Int*, 2016; 36:126-135.
14. Ioannou GN, Weiss NS, et al., "Elevated Serum Alanine Aminotransferase Activity and Calculated Risk of Coronary Heart Disease in the United States", *Hepatology*, 2006; 43:1145-1151.

15. Titcomb C, Braun R, et al., "Alcohol Abuse and Liver Enzymes (AALE): Results of an Intercompany Study of Mortality", *J Insur Med*, 2001; 33:277-289.
16. Pinkham CA, Krause KJ, "Liver Function Tests and Mortality in a Cohort of Life Insurance Applicants", *J Insur Med*, 2009; 41:170-177.
17. Ruhl CE, Everhart JE, "Elevated Serum Alanine Aminotransferase and Gamma Glutamyltransferase and Mortality in the United States Population", *Gastroenterology*, 2009; 136:477-485.
18. Mason JE, Starke RD, Van Kirk JE, "Gamma-Glutamyl Transferase: A Novel Cardiovascular Risk Biomarker", *Prev Cardiol*, 2010; 13:36-41.
19. Fraser A, Thinggaard M, et al., "Alanine Aminotransferase, Gamma-Glutamyltransferase (GGT) and All-Cause Mortality: Results from a Population –Based Danish Twins Study Alanine Aminotransferase, GGT and Mortality in Elderly Twins", *Liver Int*, 2009; 29:1494-1499.
20. Long Y, Zeng F, et al., "Gamma-Glutamyltransferase Predicts Increased Risk of Mortality: A Systematic Review and Meta-analysis of Prospective Observational Studies", *Free Radic Res*, 2014; 48:716-728.
21. Unalp-Arida A, Ruhl C, "Noninvasive Fatty Liver Markers Predict Liver Disease Mortality in the US Population", *Hepatology*, 2016; 63:1170-1183.
22. Kunutsor SK, Apekey TA, et al., "Gamma Glutamyltransferase, Alanine Aminotransferase and Risk of Cancer: Systemic Review and Meta-analysis", *Int J Cancer*, 2014; 136:1162-1170.
23. Du G, Song Z, Zhang Q, "Gamma-Glutamyltransferase is Associated with Cardiovascular and All-Cause Mortality: A Meta-analysis of Prospective Cohort Studies", *Prev Med*, 2013; 57:31-37.
24. Strasak AM, Kelleher CC, "Longitudinal Change in Serum Gamma-Glutamyltransferase and Cardiovascular Disease Mortality: A Prospective Population-Based Study in 76113 Austrian Adults", *Arterioscler Thromb Vasc Biol*, 2008; 28:1857-1865.
25. Lee DS, Evans JC, et al., "Gamma-Glutamyl Transferase and Metabolic Syndrome, Cardiovascular Disease, and Mortality Risk: The Framingham Study", *Arterioscler Thromb Vasc Biol*, 2007; 27:127-133.
26. Wannamethee SG, Lennon L, Shaper AG, "The Value of Gamma Glutamyltransferase in Cardiovascular Risk Prediction in Men with and without Diagnosed Cardiovascular Disease or Diabetes", *Atherosclerosis*, 2008; 201:168-175.
27. Strasak AM, Rapp K, et al., "Association of Gamma Glutamyltransferase and Risk of Cancer Incidence in Men: A Prospective Study", *Cancer Res*; 68:3970-7.
28. Yokoyama H, Oh, Go H, et al., "An Inverse Association between Serum Gamma Glutamyl Transpeptidase Activity and Breslow's Lifestyle Index: Its Practical Application for Screening of Subjects with Unhealthy Lifestyles", *J Occup Health*, 2006; 48:198-206.
29. Ruttman E, Brant LJ, et al., "Gamma-Glutamyltransferase as Risk Factor for Cardiovascular Disease Mortality: An Epidemiological Investigation in a Cohort of 163 944 Austrian Adults", *Circulation*, 2005; 112:2130-2137.
30. Hemelrijck MV, Jassem W, et al., "Gamma Glutamyltransferase and Risk of Cancer in a Cohort of 545,460 Persons – The Swedish AMORIS Study", *Eur J Cancer*, 2011; 47:2033-2041.
31. Fraser A, Harris R, et al., "Gamma-Glutamyltransferase is Associated with Incident Vascular Events Independently of Alcohol Intake: Analysis of the British Women's Heart and Health Study

- and Meta-Analysis”, *Arterioscler Thromb Vasc Biol*, 2008; 27:2729-2735. *Diabetes Care*, 2005; 28:1757-1762.
32. Nannipieri M, Gonzales C, et al., “Liver Enzymes, the Metabolic Syndrome and Incident Diabetes: The Mexico Diabetes Study” *Diabetes Care*, 2005; 28:1757-1762.
 33. Meisinger C, Doring A, et al., “Serum Gamma-Glutamyltransferase is a Predictor of Incident Coronary Events in Apparently Healthy Men from the General Population”, *Atherosclerosis*, 2006; 189:297-302.
 34. Haring R, Wallaschofski, H, et al., “Ultrasonographic Hepatic Steatosis Increases Prediction of Mortality Risk from Elevated Serum Gamma-Glutamyl Transpeptidase Levels”, *Hepatology*, 2009; 50:1403-1411.
 35. Kazemi L, Endler G, et al., “Gamma Glutamyltransferase and Long-Term Survival: Is it Just the Liver?”, *Clin Chem*, 2007; 940-946.
 36. Arndt V, Brenner H, et al., “Elevated Liver Enzyme Activity in Construction Workers: Prevalence, and Impact on Early Retirement and All-Cause Mortality”, *Int Arch Occup Environ Health*, 1998; 71:405-412.
 37. Tsai J, Ford ES, et al., “Past and Current Alcohol Consumption Patterns and Elevations in Serum Hepatic Enzymes among US Adults”, *Addict Behav*, 2012; 37:78-84.
 38. Hultcrantz R, Glaumann H, Lindberg G, et al. Liver investigation in 140 asymptomatic patients with moderately elevated activities of serum aminotransferases. *Scand J Gastroenterol*. 1986;21:109-113
 39. Mathiesen UL, Franzen LE, Fryden A, et al. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. *Scand J Gastroenterol*. 1999;34:85-91.
 40. Daniel S, Ben-Menachem T, Vasudevan G, et al. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. *Am J Gastroenterol*. 1999; 94:3010-3014.
 41. Van Ness M, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? *Ann Intern Med*. 1989;111:473-478.
 42. Titcomb C, “Liver Function Tests: What is the Risk?”, *J Insur Med*, 2003; 35:26-35.
 43. Ruhl CE, Everhart JE, “The Association of Low Serum Alanine Aminotransferase Activity with Mortality in the US Population”, *Am J Epidemiol*, 2013; 178:1702-1711.
 44. Liu Z, Ning H, et al., “Complex Association between Alanine Aminotransferase Activity and Mortality in the General Population: A Systematic Review and Meta-Analysis of Prospective Studies”, *PLOS ONE*, 2014; 9(3).
 45. Fulks M, Stout RL, Dolan VF, “Mortality Associated with Bilirubin Levels in Insurance Applicants”, *J Insur Med*, 2009; 41:49-53.
 46. Ong KL, Allison MA, et al., “The Relationship between Total Bilirubin Levels and Total Mortality in Older Adults: The United States National Health and Nutrition Examination Survey (NHANES) 1999-2004”, *PLOS ONE*, 2014; 9(4).
 47. Ajja R, Lee D, et al., “Usefulness of Serum Bilirubin and Cardiorespiratory Fitness as Predictors of Mortality in Men”, *Am J Cardiol*, 2011; 108:1438-1442.

48. Cho HS, Lee SW, et al., "Clinical Significance of Serum Bilirubin and Gamma-Glutamyltransferase Levels on Coronary Atherosclerosis Assessed by Multidetector Computed Tomography", *Nutr Metab Cardiovasc Dis*, 2015; 25:677-85.
49. Singh G, Reflex Testing for Carbohydrate-Deficient Transferrin (CDT) in Insurance Applicants with Elevated High Density Lipoprotein Cholesterol (HDL)", *J Insur Med*, 2015; 45:42-47.
50. Papastergiou V, Tsochatzis E, Burroughs AK, "Non-Invasive Assessment of Liver Fibrosis", *Ann Gastroenterol*, 2012; 25:218-231.
51. Fallatah HI, "Non-invasive Biomarkers of Liver Fibrosis: An Overview", *Adv Hepatol*, 2014
52. Ke P, Zhong L, et al., "Association of the Serum Transaminase with Mortality among the US Elderly Population", *J Gastroenterol Hepatol*, 2022; 37:946-953.
53. Kim KN, Joo J, et al., "Associations of Serum Liver Enzyme Levels and their Changes Over Time with All-Cause and Cause-Specific Mortality in the General Population: A Large-Scale National Health Screening Cohort Study", *BMJ Open*, 2019; e026965. doi:10.1136/bmjopen-2018-026965.
54. Ho FR, Ferguson LD, et al., "Association of Gamma-Glutamyltransferase Levels with Total Mortality, Liver-Related and Cardiovascular Outcomes: A Prospective Cohort Study in the UK Biobank", *EClinicalMedicine*, 2022; May 12; 48-101435. doi: 10.1016/j.eclinm.2022.101435. eCollection 2022 Jun.
55. Hernaez R, Yeh HC, et al., "Elevated ALT and GGT Predict All-Cause Mortality and Hepatocellular Carcinoma in Taiwanese Male: A Cohort Study", *Hepatol Int*, 2013; 7: 1040-1049.
56. Katzke V, Johnson T, et al., "Circulating Liver Enzymes and Risks of Chronic Diseases and Mortality in the Prospective EPIC-Heidelberg Case-Cohort Study", *BMJ Open*, 2020; 10: e033532. doi: 10.1136/bmjopen-2019-033532.
57. Yuwaki K, Shimazu T, et al., "Association between Serum Liver Enzymes and All-Cause Mortality: The Japan Public Health Center-Based Prospective Study", *Liver Int*, 2019; 39:1566-1576.
58. Xie K, Chen CH, et al., "Loss of Life Expectancy by 10-Years or More from Elevated Aspartate Aminotransferase: Finding Aspartate Aminotransferase a Better Mortality Predictor for All-Cause and Liver-Related than Alanine Aminotransferase", *Am J Gastroenterol*, 2019; 114:1478-1487.
59. Wang SF, Kai J, et al., "The Value of Aspartate Aminotransferase and Alanine Aminotransferase in Cardiovascular Disease Risk Assessment", *Open Heart*, 2015; 2: e000272. doi: 10.1136/openhrt-2015-000272.

Hepatitis B

60. "HBV Epidemiology", <https://www.hepatitisB.uw.edu/go/screening-diagnosis/hbv-epidemiology/core-concept/all>.

61. WHO Hepatitis B Fact Sheet 9 April 2024 www.who.int/news-room/fact-sheet/detail/hepatitis-b.
62. CDC 2022 Viral Hepatitis B Surveillance Report April 4,2024 www.cdc.gov/hepatitis-surveillance-2022/hepatitis-b/index.html
63. Jeng WJ, Papatheodoridis GV, Lok AS, "Hepatitis B", Lancet, 2023; 401:1039-1052.
64. Asadem DA, Segbefia SP, et al., "Hepatitis B Virus Infection: A Mini Review", Rev Viruses, 2024 May 3; 16(5):724. doi: 10.3390/v16050724.
65. Teo EK, Lok ASF, "Epidemiology, Transmission and Prevention of Hepatitis B Virus Infection", Kaplan SL, Esteban R, Mitty J, eds. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com> (Accessed on June 13, 2025.)
66. Saitta C, Pollicino T, Raimondo G, "Occult Hepatitis B Virus Infection: an Update", Viruses, 2022 Jul 8; 14(7): 1504. Doi: 10.3390/v14071504.
67. Rahatullah HS, "Current and Emerging Therapeutic Strategies for Chronic Hepatitis B Virus Infection: A Review", European Journal of Medical and Health Sciences, 2025; 7(3):1-9 <https://doi.org/10.24018/ejmed2025.7.3.2280>.
68. Terrault NA, Lok AS, et al., "Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance", doi: 10.1002/hep.29800.
69. Wilkins T, Zimmerman D, Schade RR, "Hepatitis B: Diagnosis and Treatment", Am Fam Physician, 2010; 81:965-872.
70. Liang TJ, "Hepatitis B: The Virus and Disease", Hepatology, 2009; 49(5 Suppl):S13-S21.
71. Schillie S, Vellozzi C, Reingold A, et al., "Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices", MMWR Recomm Rep, 2018; 67(No. 1):1-31.
72. Grimm D, Thimme R, Blum HE, "HBV Life Cycle and Novel Drug Targets", Hepatol Int, 2011; 5:644-653.
73. Sunbul M, "Hepatitis B Virus Genotypes: Global Distribution and Clinical Importance", World J Gastroenterol, 2014, 20:5427-5434.
74. Song JE, Kim DY, "Diagnosis of Hepatitis B", Ann Transl Med, 2016; 4:338.
75. Schweitzer A, Horn J, et al., "Estimation of Worldwide Prevalence of Chronic Hepatitis B Virus Infection: A Systematic Review of Data Published Between 1965 and 2013", Lancet. 2015 Oct 17; 386(10003):1546-55. doi: 10.1016/S0140-6736(15)61412-X. Epub 2015 Jul 28.
76. "Interpretation of Hepatitis B Serologic Test Results", www.cdc.gov/hepatitis
77. Sarpel D, Carter D, et al., "An Update On the Management of Chronic Hepatitis B and C Infection", Clinical Pharmacist, 2017; <https://www.pharmaceutical-journal.com/research/an-update-on-the-management-of-chronic-hepatitis-b-and-c-infection/20203306.article>
78. "Hepatitis B and C Treatments"
<https://www.fda.gov/forpatients/illness/hepatitisbc/ucm408658.htm>
79. McMahon BJ, "Natural History of Chronic Hepatitis B", Clin Liver Dis, 2010; 14:381-396.
80. Fiel MI, "Pathology of Chronic Hepatitis B and Chronic Hepatitis C", Clin Liver Dis, 2010; 14:555-575.
81. Chen CJ, Yan HI, "Natural History of Chronic Hepatitis B REVEALed", J Gastroenterol Hepatol, 2011; 26:628-638.

82. Iloeje UH, Yang HI, et al., "Risk and Predictors of Mortality Associated with Chronic Hepatitis B Infection", *Clin Gastroenterol Hepatol*, 2007; 5:921-931.
83. Iloeje UH, Yang HI, et al., "Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load", *Gastroenterology*, 2006; 130:678-686.
84. Chen JD, Yang HI, et al., "Carriers of Inactive Hepatitis B Virus are Still at Risk for Hepatocellular Carcinoma and Liver Related Death", *Gastroenterology*, 2010; 138:1747-1754.
85. Chen CJ, Yang HI, et al., "Risk of Hepatocellular Carcinoma Across a Biologic Gradient of Serum Hepatitis B Virus DNA Levels", *JAMA*, 2006; 295:65-73.
86. Hsu A, Lai CL, Yuen MF, "Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection", *Curr Hepatitis Rep*, 2011; 10:106-111.
87. Yang HI, Sherman M, et al., "Nomograms for Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection", *J Clin Oncol*, 2010; 14:2437-2444.
88. Chen CJ, Hussain M, Lok ASF, "Quantitative Serum HBV DNA Levels During Different Stages of Chronic Hepatitis B Infection", *Hepatology*, 2002; 36:1408-1415.
89. Pokorski R, Ohlmer U, "Long-term Morbidity and Mortality in Chinese Insurance Applicants Infected with Hepatitis B Virus", *J Insur Med*, 2001; 33:143-164.
90. Hadziyannis SJ, Vassilopoulos D, "Hepatitis B e Antigen-Negative Chronic Hepatitis B", *Hepatology*, 2001; 34:617-624.
91. Jafri SMR, Lok ASF, "Antiviral Therapy for Chronic Hepatitis B", *Clin Liver Dis*, 2010;14:425-438.
92. Valmaki A, "Molecular Testing in the Diagnosis and Management of Chronic Hepatitis B" *Clin Microbiol Rev*, 2007; 20:426-439.
93. Shah SM, Singh SP, "Hepatitis B Virus Serology and Interpretation", *Hep B Ann*, 2007; 4:39-54.
94. Crook PD Jones Me, Hall AJ, "Mortality of Hepatitis B Surface Antigen-Positive Blood Donors in England and Wales", *Int J Epidemiol*, 2003; 32:118-124.
95. Manno M, Camma C, et al., "Natural History of HBV Carriers in Northern Italy Morbidity and Mortality After 30 Years", *Gastroenterology*, 2004; 127:756-763
96. Fattovich G, Olivari N, et al., "Long-Term Outcome of Chronic Hepatitis B in Caucasian Patients: Mortality after 25 Years", *Gut*, 2008; 57:84-90.